NDA 022334 · Novartis
Afinitor
Everolimus · Oral · Kinase Inhibitor; mTOR Inhibitor Immunosuppressant
NovelAccelerated approvalPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Jun 1, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2009
Mar 30, 2009
Approved uses
16
Original approval plus efficacy supplements
Registered trials
881
126 Phase 3, 57 recruiting
FAERS reports
49,330
38,255 serious, 10,696 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jun 1, 2026.
AFINITOR is a kinase inhibitor indicated for the treatment of: Postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole. ( 1.1 ) Adults with progressive neuroendocrine tumors of pancreatic origin (PNET) and adults with progressive, well-differentiated, non-functional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin that are unresectable, locally advanced or metastatic. Limitations of Use: AFINITOR is not indicated for the treatment of patients with functional carcinoid tumors. ( 1.2 ) Adults with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib. ( 1.3 ) Adults with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery. ( 1.4 ) AFINITOR and AFINITOR DISPERZ are kinase inhibitors indicated for the treatment of adult and pediatric patients aged 1 year and older with TSC who have subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected. ( 1.5 ) AFINITOR DISPERZ is a kinase inhibitor indicated for the adjunctive treatment of adult and pediatric patients aged 2 years and older with TSC-associated partial-onset seizures. ( 1.6 ) 1.1 Hormone Receptor-Positive, HER2-Negative Breast Cancer AFINITOR ® is indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer in combination with exemestane, after failure of treatment with letrozole or anastrozole. 1.2 Neuroendocrine Tumors (NET) AFINITOR is indicated for the treatment of adult patients with progressive neuroendocrine tumors of pancreatic origin (PNET) with unresectable, locally advanced or...
Mechanism: Everolimus is an inhibitor of mammalian target of rapamycin (mTOR), a serine-threonine kinase, downstream of the PI3K/AKT pathway. The mTOR pathway is dysregulated in several human cancers and in tuberous sclerosis complex (TSC). Everolimus binds to an intracellular protein, FKBP-12, resulting in an inhibitory complex formation with mTOR complex 1 (mTORC1) and thus inhibition of mTOR kinase activity. Everolimus reduced the activity of S6 ribosomal protein kinase (S6K1) and eukaryotic initiation factor 4E-binding protein (4E-BP1), downstream effectors of mTOR, involved in protein synthesis....
Therapeutic areas: Oncology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 30, 2021 Supplement 50 · Efficacy Label
- Apr 10, 2018 Supplement 40 · Efficacy OrphanLabelLetter
- Sep 26, 2017 Supplement 39 · Efficacy LabelLetter
- Feb 26, 2016 Supplement 36 · Efficacy · priority review OrphanLetterLabel
- Feb 18, 2016 Supplement 35 · Efficacy · priority review Letter
- Jan 29, 2016 Supplement 32 · Efficacy LetterLabel
- Sep 18, 2015 Supplement 31 · Efficacy LetterLabel
- May 22, 2015 Supplement 30 · Efficacy LabelLetter
- Dec 18, 2014 Supplement 27 · Efficacy LabelLetter
- Nov 6, 2013 Supplement 22 · Efficacy LetterLabel
- Jul 20, 2012 Supplement 16 · Efficacy LabelReviewLetter
- Apr 26, 2012 Supplement 17 · Efficacy · priority review OrphanLabelLetter
- Mar 30, 2012 Supplement 14 · Efficacy LabelLetter
- May 5, 2011 Supplement 9 · Efficacy · priority review LetterLabel
- Oct 29, 2010 Supplement 6 · Efficacy · priority review Accelerated approvalLetterLabel
- Mar 30, 2009 Original approval · Type 1 - New Molecular Entity · priority review NovelAccelerated approvalPediatric Written RequestPediatric Clinical Pharmacology ReviewPediatric Medical Review
4 products under this application
- AFINITOR · EVEROLIMUS 7.5MG · TABLET, ORAL · Prescription · TE AB
- AFINITOR · EVEROLIMUS 10MG · TABLET, ORAL · Prescription · TE AB
- AFINITOR · EVEROLIMUS 2.5MG · TABLET, ORAL · Prescription · TE AB
- AFINITOR · EVEROLIMUS 5MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Everolimus" as an intervention, any sponsor and status, largest first.
- The Dual Antiplatelet Therapy Study (DAPT Study)Pivotal-lookingCompleted
Baim Institute for Clinical ResearchAcademic, hospital or other
NCT00977938 · 25,682 participants · Start Oct 2009 · Primary completion Jun 2014
Drug: Placebo & Aspirin; Clopidogrel & Aspirin, Prasugrel & Aspirin · For: Coronary Artery Disease
Sites: Fairhope, Alabama; Gilbert, Arizona; Phoenix, Arizona · 256 sites in all
- Colchicine and Spironolactone in Patients with MI / SYNERGY Stent RegistryPivotal-lookingCompleted
Population Health Research InstituteAcademic, hospital or other
NCT03048825 · 7,264 participants · Start Feb 1, 2018 · Primary completion Aug 9, 2024
Drug: Colchicine; Spironolactone and 2 more · For: ST Elevation Myocardial Infarction; Non ST Elevation Myocardial Infarction
Sites: Bakersfield, California; Washington D.C., District of Columbia; Chicago, Illinois · 109 sites in all
- ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-3 StudyPivotal-lookingStatus unknown
Kyoto University, Graduate School of MedicineAcademic, hospital or other
NCT04609111 · 6,002 participants · Start Jan 29, 2021 · Primary completion Dec 31, 2023
Drug: No aspirin; 1-month DAPT · For: Acute Coronary Syndrome
Sites: Kyoto, Japan
- Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis - SAfety & EffectiveneSS of Drug-ElUting Stents & Anti-platelet REgimenPivotal-lookingStatus unknown
Seoul National University HospitalAcademic, hospital or other
NCT01267734 · 3,750 participants (planned) · Start Jun 2010 · Primary completion Dec 2011
Drug: Triple anti-platelet therapy (TAT); Double-dose clopidogrel anti-platelet therapy (DDAT) · For: Coronary Heart Disease
Sites: Seoul, South Korea
- Harmonizing Optimal Strategy for Treatment of Coronary Artery Diseases Trial - Comparison of REDUCTION of PrasugrEl Dose & POLYmer TECHnology in ACS Patients (HOST REDUCE POLYTECH RCT Trial)Pivotal-lookingCompleted
Seoul National University HospitalAcademic, hospital or other
NCT02193971 · 3,429 participants · Start Jul 2014 · Primary completion Oct 2020
Drug: Prasugrel 5mg · For: Acute Coronary Syndrome
Sites: Seoul, South Korea
- ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study for the Patients With ACSPivotal-lookingStatus unknown
Kyoto University, Graduate School of MedicineAcademic, hospital or other
NCT03462498 · 3,008 participants · Start Apr 2, 2018 · Primary completion Dec 31, 2021
Drug: 1-months DAPT; 12-month DAPT · For: Acute Coronary Syndrome; Acute Myocardial Infarction; Coronary Artery Disease and 2 more
Sites: Kyoto, Japan
Boston Scientific CorporationIndustry
NCT01589978 · 2,681 participants · Start May 2012 · Primary completion Aug 2014
Drug: Aspirin; P2Y12 antagonist · For: Coronary Artery Disease
Sites: Huntsville, Alabama; Mobile, Alabama; Jonesboro, Arkansas · 52 sites in all
- Bevacizumab, Everolimus (RAD001), and Lapatinib as Neoadjuvant Chemotherapy Regimes for Primary Breast CancerPivotal-lookingCompleted
GBG Forschungs GmbHAcademic, hospital or other
NCT00567554 · 2,600 participants · Start Oct 2007 · Primary completion Aug 2011
Drug: epirubicin - cyclophosphamide / docetaxel; epirubicin - cyclophosphamide / docetaxel + bevacizumab and 4 more · For: Breast Cancer
Sites: Frankfurt am Main, Germany
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- death6,201
- malignant neoplasm progression4,730
- diarrhoea4,043
- fatigue3,792
- stomatitis3,131
- nausea2,831
- dyspnoea2,603
- drug ineffective2,360
- decreased appetite2,113
- pyrexia2,107
- vomiting2,091
- rash1,985
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 2 |
| 2005 | 1 |
| 2006 | 5 |
| 2007 | 15 |
| 2008 | 34 |
| 2009 | 188 |
| 2010 | 928 |
| 2011 | 1,441 |
| 2012 | 2,329 |
| 2013 | 2,124 |
| 2014 | 2,289 |
| 2015 | 3,950 |
| 2016 | 4,796 |
| 2017 | 3,988 |
| 2018 | 4,749 |
| 2019 | 4,680 |
| 2020 | 4,217 |
| 2021 | 3,392 |
| 2022 | 2,678 |
| 2023 | 2,517 |
| 2024 | 2,108 |
| 2025 | 1,586 |
| 2026 | 1,313 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Afinitor (Everolimus)
2024 spending
$17.7M
Beneficiaries
151
905 claims
Per beneficiary
$117,391
$629.78 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $302,356,560 |
| 2021 | $216,178,594 |
| 2022 | $100,030,446 |
| 2023 | $29,755,095 |
| 2024 | $17,726,015 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma.
Choueiri TK, Powles T, Peltola K, et al. · N Engl J Med 2024 · Clinical Trial, Phase III, Multicenter Study
- Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.
Motzer R, Alekseev B, Rha SY, et al. · N Engl J Med 2021 · Clinical Trial, Phase III, Comparative Study
- Everolimus for advanced pancreatic neuroendocrine tumors.
Yao JC, Shah MH, Ito T, et al. · N Engl J Med 2011 · Clinical Trial, Phase III, Multicenter Study
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.
Motzer RJ, Escudier B, McDermott DF, et al. · N Engl J Med 2015 · Clinical Trial, Phase III, Comparative Study
- Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.
Baselga J, Campone M, Piccart M, et al. · N Engl J Med 2012 · Clinical Trial, Phase III, Comparative Study
- Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation.
Pascual J, Berger SP, Witzke O, et al. · J Am Soc Nephrol 2018 · Equivalence Trial, Multicenter Study
Sponsor: Novartis
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.